BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...with an internal portfolio of immuno-oncology agents. Szela was previously CEO of rare disease company Novelion Therapeutics Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...hired Ben Harshbarger as SVP, general counsel. He was general counsel and interim CEO at Novelion Therapeutics Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Inc. (NASDAQ:AKCA) hired Michael Price as EVP and CFO. He held the same position at Novelion Therapeutics Inc....
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...Amryt Pharma plc (LSE:AMYT; Euronext:AMYT) completed its acquisition of the Aegerion Pharmaceuticals Inc. unit of Novelion Therapeutics Inc....
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

...exclusive rights to the therapy from Ionis Pharmaceuticals Inc. Aegerion is now a subsidiary of Novelion Therapeutics Inc....
...Oaks, Calif. Amryt Pharma plc (LSE:AMYT; ISE:AYP), Dublin, Ireland Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Novelion Therapeutics Inc....
BioCentury | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

...in a deal valuing the combined company at about $310 million. Aegerion, a subsidiary of Novelion Therapeutics Inc....
...eligible for royalties; financial terms were not disclosed. Chris Lieu, Staff Writer Alphabet Inc. Amryt Pharma plc Fundacion Medina Novartis AG Novelion Therapeutics Inc. Otsuka...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...hired Pamela Bradt as CSO. Bradt was CMO at Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc....
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...which is now part of Takeda Pharmaceuticals Co. Ltd. Aegerion is now a unit of Novelion Therapeutics Inc....
...Cambridge, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Novelion Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

...U.K.) hired Jeffrey Hackman as president of its U.S. operations. Hackman was acting CEO of Novelion Therapeutics Inc....
Items per page:
1 - 10 of 32
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...with an internal portfolio of immuno-oncology agents. Szela was previously CEO of rare disease company Novelion Therapeutics Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...hired Ben Harshbarger as SVP, general counsel. He was general counsel and interim CEO at Novelion Therapeutics Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Inc. (NASDAQ:AKCA) hired Michael Price as EVP and CFO. He held the same position at Novelion Therapeutics Inc....
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...Amryt Pharma plc (LSE:AMYT; Euronext:AMYT) completed its acquisition of the Aegerion Pharmaceuticals Inc. unit of Novelion Therapeutics Inc....
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

...exclusive rights to the therapy from Ionis Pharmaceuticals Inc. Aegerion is now a subsidiary of Novelion Therapeutics Inc....
...Oaks, Calif. Amryt Pharma plc (LSE:AMYT; ISE:AYP), Dublin, Ireland Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Novelion Therapeutics Inc....
BioCentury | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

...in a deal valuing the combined company at about $310 million. Aegerion, a subsidiary of Novelion Therapeutics Inc....
...eligible for royalties; financial terms were not disclosed. Chris Lieu, Staff Writer Alphabet Inc. Amryt Pharma plc Fundacion Medina Novartis AG Novelion Therapeutics Inc. Otsuka...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...hired Pamela Bradt as CSO. Bradt was CMO at Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc....
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...which is now part of Takeda Pharmaceuticals Co. Ltd. Aegerion is now a unit of Novelion Therapeutics Inc....
...Cambridge, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Novelion Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

...U.K.) hired Jeffrey Hackman as president of its U.S. operations. Hackman was acting CEO of Novelion Therapeutics Inc....
Items per page:
1 - 10 of 32